MUVON Therapeutics AG

MUVON enables healthy aging! We reverse age- or damage-related disability through functional skeletal muscle regeneration. MUVON's proprietary, cell-based regenerative platform technology induces successful muscle restoration, using a low-risk, minimally-invasive treatment modality, bringing personalized medicine to patients with high unmet medical need. In our first pipeline indication, we successfully completed a PhI clinical trial, resulting in functional restoration of the sphincter muscle of patients, suffering from a highly-debilitating disease,stress urinary incontinence, affecting 40% women over 40 and 20% men over 60. Our platform therapy holds potential for a transformative therapeutic option in Women's Health. With available (PhII interim) data we are raising now our SerA.